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Abstract
Purpose Analysis of anti-Müllerian hormone (AMH) is be-
coming of recognized importance in reproductive medicine,
but assays are not standardized. We have evaluated the corre-
lation between the new Gen II ELISA kit (Beckman-Coutler)
and the older ELISA kits by Immunotech (IOT) and Diagnos-
tic Systems Laboratories (DSL).
Methods A total of 56 archived serum samples from
patients with subfertility or reproductive endocrine disorders
were retrieved and assayed in duplicate using the three
AMH ELISA kits . The samples covered a wide range of
AMH concentrations (1.9 to 142.5 pmol/L).
Results We observed good correlations between the new
(AMH Gen II) and old AMH assay kits by IOT and DSL
(R200.971 and 0.930 respectively). The regression equations
were AMH (Gen II)01.353 × AMH (IOT)+0.051 and AMH
(Gen II)01.223 × AMH (DSL) – 1.270 respectively.
Conclusions AMH concentrations using the Gen II kit are
slightly higher than those from the IOT and DSL kits. Stan-
dardization of assay results worldwide is urgently required but
this analysis facilitates the interpretation of values obtained
historically and in future studies using any of the 3 assays
available. Meanwhile, adapting clinical cut-offs from previous-
ly published work by direct conversion is not recommended.
Keywords Anti-Mullerian hormone . ELISA kit
Introduction
Anti-Müllerian hormone (AMH), also known as Müllerian-
inhibiting substance, is a dimeric glycoprotein that belongs to
the transforming growth factor-beta family. It is involved in the
regression of the Müllerian ducts during male fetal develop-
ment [12]. In the female, AMH is solely produced by the
granulosa cells of preantral and small antral follicles, and
regulates ovarian activity and follicular steroidogenesis. Be-
cause of this exclusive source of production in the adult female,
AMH is a potentially useful marker of ovarian function, and
there have been increasing reports on its clinical utility [1].
Because of its stable production throughout the menstrual
cycle with clinically insignificant intra- and inter-cycle var-
iation [9, 20], and that its serum concentration is not influ-
enced by the use of exogenous hormones [16], AMH may
serve as a clinically useful diagnostic tool in differentiating
the different causes of secondary oligo-amenorrhoea with
very good diagnostic accuracy as well as its utility in the
research context. Serum AMH concentration is significantly
increased by 2 to 3 times in women with WHO group 2
anovulation including polycystic ovary syndrome (PCOS),
and is significantly reduced to very low levels in premature
ovarian failure (POF), while remaining unchanged in hypo-
gonadotrophic hypogonadism and hyperprolactinaemia
compared to ovulatory women [10, 17].
In in-vitro fertilization (IVF) treatment cycles, basal serum
AMH level is significantly correlated with the number of
follicles obtained after stimulation and the number of retrieved
oocytes, and is useful in prediction of suboptimal and
Capsule AMH concentrations using the Gen II kit correlate well with,
although being slightly higher than, those from the IOT and DSL kit.
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excessive ovarian responses upon ovarian stimulation [1, 3, 4,
18]. Although most reports indicate a poor predictive value of
AMH on pregnancy rate in the fresh cycle of IVF treatment, as
reviewed in a recent meta-analysis [3], it has been suggested
that it does give some prediction of pregnancy [11], particu-
larly when taking both the fresh and frozen embryo transfers
into account [7, 14]. In controlled ovarian stimulation and
intrauterine insemination, a recent study also showed that
higher serum AMH level was associated with significantly
higher cumulative live birth rate [15].
Worldwide, two commercially available ELISA kits for
determination of AMH have been available, manufactured
by Diagnostic Systems Laboratories, Inc. (DSL) and
Immunotech (IOT), both under the umbrella of Beckman
Coulter, Inc. Recently, a new ELISA kit, called “AMH
Gen II ELISA”, has been marketed by Beckman Coulter
to replace the two older kits. According to information
from the manufacturer, the AMH Gen II ELISA kit uses
the same antibody as in the DSL kit but the standards of
the IOT assay kit [8].
Guidance is therefore required to interpret the growing
literature derived from using the different assay systems avail-
able. The different assays have been discussed [19] but no
studies have directly compared the 3 available assay systems
on the same sample set. We carried out this analysis to eval-
uate the correlation between the new and old AMH ELISA
kits by running parallel assays on the same batch of serum
samples using the three kits mentioned, so as to find out the
correlation between the results of the old and new kits, and to
validate the new kit for future clinical and research utility.
Methods
We analysed a total of 56 serum samples taken from patients
suffering from polycystic ovary syndrome or subfertility
(with causes including male factor, tubo-peritoneal factor,
endometriosis and unexplained subfertility) who attended
the Edinburgh Fertility and Reproductive Endocrine Centre,
Edinburgh, United Kingdom with informed, written consent
and local ethical committee approval. Parallel assays were
repeated using the three AMH ELISA kits as follows:
(1) Active MIS/AMH ELISA (catalogue number DSL-10-
14400) (DSL, Webster, TX, USA), which has a sensi-
tivity of 0.04 pmol/l, and reported intra- and inter-assay
coefficients of variation of less than 4.6 % and 8.0 %
respectively according to the product insert;
(2) EIA AMH/MIS (catalogue number A16507) (IOT,
Marseille, France), which has a sensitivity of 0.7
pmol/l, and reported intra- and inter-assay coefficients
of variation of less than 12.3 % and 14.2 % respectively
according to the product insert;
(3) AMH Gen II (catalogue number A79765) (Beckman
Coulter, Chaska, MN, USA), which has a sensitivity of
0.57 pmol/l, and reported intra- and inter-assay coef-
ficients of variation of less than 5.4 and 5.6 % respec-
tively according to the product insert.
All samples were assayed in duplicate on all the three kits.
Correlation of AMH concentrations determined by the
different kits were analysed by the Passing and Bablok
regression model using the MedCalc version 11.6 software.
Results
Comparative analysis was performed on a total of 56 serum
samples. The median age of the subjects was 31.5 (range
18.6–40.4) years. The AMH concentration ranged from 1.9
to 142.5 pmol/l based on the Gen II kit.
The respective scatter plot diagrams with the curve fit, as
well as the Bland-Altman plots are shown in Fig. 1. There
were good correlations of the Gen II kit with both DSL (R20
0.930, p<0.0001) and IOT kits (R200.971, p<0.0001). On
the Passing and Bablok regression model, the regression
equation correlating the Gen II and DSL kits was: AMH
(Gen II)01.223 × AMH (DSL) –1.270 pmol/L, while
that correlating the Gen II and IOT kits was: AMH (Gen II)0
1.353 × AMH (IOT)+0.051 pmol/L. The regression equation
correlating the IOT and DSL kits was: AMH (IOT)00.910×
AMH (DSL) –1.103 pmol/L (R200.906, p<0.0001). All three
regression curves showed no significant deviation from line-
arity (p>0.05). The Bland-Altman plots confirmed that the
values obtained with the Gen II kit were systematically higher
than those from the IOT and DSL kits.
It was observed that the difference between values obtained
from two kits tended to be smaller and the dispersion of the
difference tended to be greater in samples with AMH values
greater than 100 pmol/L. If only samples with AMH values of
less than 100 pmol/L in the X-axis were analysed, the follow-
ing regression equations are obtained:
AMH Gen IIð Þ ¼ 1:376 AMH IOTð Þ  0:679 pmol=L
AMH Gen IIð Þ ¼ 1:330 AMH DSLð Þ  4:174 pmol=L
AMH IOTð Þ ¼ 0:973 AMH DSLð Þ  2:963 pmol=L
Discussion
Our results demonstrate excellent correlation between the
new Gen II kit and both the DSL and IOT kits. This is
reassuring and allows general interpretation of data obtained
using all 3 systems. According to our regression equations,
AMH values obtained with the new assay kit will be some
35 % and 22 % higher than with the IOT and DSL kits
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respectively. As revealed in the Bland-Altman plots, the
variations in differences between the Gen II and the older
kits appeared to be greater at higher AMH values. However,
cut-offs for clinical utility are mostly at the lower range of
values and hence variations at the higher end are probably of
less clinical importance. When only samples with AMH
values less than 100 pmol/L were taken, the Gen II kit gave
values about 38 % and 33 % higher than with the IOT and
DSL kits respectively.
Two previous studies have compared the Gen II kit to the
DSL [22] and IOT kits [8]. The former gave a regression
equation: Gen II01.40×DSL –0.62 pmol/L (R200.9216, n0
271, with AMH concentration ranging from 0 to about 100
pmol/l), while the latter gave a regression equation: Gen II0
1.0018×IOT ng/ml (R200.98, n0120, with AMH concentra-
tion ranging from 0–20 ng/ml i.e. 0–143 pmol/l). Thus both
our finding and that by Wallace et al. [22] revealed higher
values given by the Gen II assay than the DSL assay, and both
reported comparable conversion factors at AMH values of less
than 100 pmol/L. The Gen II kit is stated to be calibrated to the
IOT kit and yet we observed 35 % higher values with the Gen
II kit, in contrast to that reported by Kumar et al. [8]. The
reason for this discrepancy is not certain.
There are also several reports on comparison of AMH
values between the IOT and DSL kits [2, 5, 6, 13, 21].
Strikingly, these show widely different regression equations,
with both lower and comparable AMH values with the DSL
kit compared with the IOT kit being reported. In contrast,
our findings revealed a slightly higher instead of lower value
with the DSL kit compared with the IOT kit.
A point to note is that this analysis was based on the unit
pmol/l. Users who adopt the unit ng/ml for AMH can refer
to the conversion formula: 1 ng/ml07.18 pmol/l.
Based on these discrepant findings among studies, it is
obvious that an international standard should be urgently
developed before widespread clinical applications of AMH
assays are further developed. We do not recommend adapting
clinical cut-offs from previously published work by direct
conversion. Instead, it may be more appropriate to redefine
such cut-off values for clinical application by further studies
using a unified international standard. As the only commercial
ELISA kit for AMH assay at the moment replacing the two
older ones, the AMHGen II ELISA kit could potentially serve
this role. Certainly an automated system, which could further
improve the efficiency and precision of the assay, is awaited.
When these are available, further validation studies will be
required to determine universal standardised cut-off values for
various clinical applications.
In conclusion, we have shown a good correlation be-
tween the new and old AMH assay kits. The introduction
of the new kit appears to be a useful substitute for the two
old assay kits, taking into account the altered calibration.
(a) Gen II vs DSL
AMH (Gen II) = 1.223 AMH (DSL) – 1.270 pmol/L



























(b) Gen II vs IOT
AMH (Gen II) = 1.353 AMH (IOT) + 0.051 pmol/L



























AMH (IOT) = 0.910 × AMH (DSL) – 1.103 pmol/L





























Fig. 1 Correlation between three commercial ELISA kits for determination of anti-Mullerian hormone (AMH). The upper panels represent the
Passing and Bablok regression whereas the lower panels represent the Bland-Altman plot
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However universal standardization of assay results world-
wide and the determination of clinically meaningful cut-off
values is essential for the robust and widespread use of
AMH in clinical and research practice.
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